Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofirnoflast in Lower-Risk Myelodysplastic Syndromes
NCT07738510Phase 2Not yet recruiting
- Sponsor
- Halia Therapeutics
- Start
- Nov 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of ofirnoflast in myelodysplastic syndrome (MDS), anemia, sponsored by Halia Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ofirnoflast
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT07738510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738510.